[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Alkermes Plc (ALKS)

Alkermes Plc (ALKS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,887,052
  • Shares Outstanding, K 166,676
  • Annual Sales, $ 1,476 M
  • Annual Income, $ 241,660 K
  • EBIT $ 204 M
  • EBITDA $ 231 M
  • 60-Month Beta 0.38
  • Price/Sales 4.77
  • Price/Cash Flow 25.25
  • Price/Book 4.01

Options Overview Details

View History
  • Implied Volatility 46.32% (-1.97%)
  • Historical Volatility 38.99%
  • IV Percentile 16%
  • IV Rank 11.51%
  • IV High 112.83% on 07/17/25
  • IV Low 37.67% on 09/09/25
  • Expected Move (DTE 15) 1.57 (3.71%)
  • Put/Call Vol Ratio 0.13
  • Today's Volume 36
  • Volume Avg (30-Day) 1,272
  • Put/Call OI Ratio 0.74
  • Today's Open Interest 10,418
  • Open Int (30-Day) 9,171
  • Expected Range 40.86 to 44.00

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 6
  • High Estimate $0.02
  • Low Estimate $-0.18
  • Prior Year $0.52
  • Growth Rate Est. (year over year) -111.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.20 +27.98%
on 05/04/26
42.83 -0.79%
on 05/29/26
+9.11 (+27.29%)
since 05/01/26
3-Month
27.00 +57.37%
on 03/19/26
42.83 -0.79%
on 05/29/26
+13.29 (+45.51%)
since 03/03/26
52-Week
25.17 +68.85%
on 09/08/25
42.83 -0.79%
on 05/29/26
+11.22 (+35.88%)
since 06/03/25

Most Recent Stories

More News
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

— Company to Present 11 Posters Demonstrating Commitment to Advancing Innovative Research for People Living With Chronic Psychiatric and Neurological Disorders —

ALKS : 42.61 (+3.12%)
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

– Real-World Evidence of Positive Impact of LYBALVI ® (olanzapine and samidorphan) on Treatment Patterns and Rates of Relapse Among Patients with Schizophrenia or Bipolar I Disorder,...

ALKS : 42.61 (+3.12%)
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

– LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported...

ALKS : 42.61 (+3.12%)
Alkermes: Q1 Earnings Snapshot

Alkermes: Q1 Earnings Snapshot

ALKS : 42.61 (+3.12%)
Alkermes plc Reports First Quarter 2026 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended March 31, 2026 and financial expectations for full year 2026. To view the detailed first quarter 2026 ...

ALKS : 42.61 (+3.12%)
Alkermes Reports Tomorrow With Sleep Medicine Acquisition Finally On the Books

Barchart Research What to Expect from ALKS Earnings ALKS Generated May 4, 2026 Current Price $34.17 EPS Estimate $$-0.57 Consensus Rating Moderate Buy Average Move 4.69% Alkermes Reports Tomorrow With...

ALKS : 42.61 (+3.12%)
Alkermes to Report First Quarter Financial Results on May 5, 2026

Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Tuesday, May 5, 2026 to discuss the company’s first quarter financial results....

ALKS : 42.61 (+3.12%)
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

— Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigue— ...

ALKS : 42.61 (+3.12%)
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

— 56-Week Post Hoc Analysis Demonstrated Sustained Reduction in Hard-to-Treat Negative Symptoms —

ALKS : 42.61 (+3.12%)
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Alkermes plc (Nasdaq: ALKS) today announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy...

ALKS : 42.61 (+3.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Alkermes plc, formed by the merger of Waltham, MA-based Alkermes, Inc. and Elan Drug Technologies (EDT), is a fully integrated global biopharmaceutical company that utilizes proprietary technologies to research, develop and commercialize, both with partners and on its own pharmaceutical products in major...

See More

Key Turning Points

3rd Resistance Point 43.01
2nd Resistance Point 42.47
1st Resistance Point 41.90
Last Price 42.61
1st Support Level 40.79
2nd Support Level 40.25
3rd Support Level 39.68

See More

52-Week High 42.83
Last Price 42.61
Fibonacci 61.8% 36.08
Fibonacci 50% 34.00
Fibonacci 38.2% 31.91
52-Week Low 25.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.